PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Clinical trials for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis study tests a drug called PLX038 in people with ovarian, peritoneal, or fallopian tube cancer that has spread and no longer responds to platinum chemotherapy. The goal is to see if PLX038 can shrink tumors by blocking enzymes cancer cells need to grow. About 43 adults with a…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, vismodegib and atezolizumab, in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can shrink tumors or slow disease prog…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
Ovarian cancer Patients' own immune cells supercharged to fight tumors
Disease control Recruiting nowThis early-phase study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), train them in a lab to recognize a protein called MUC1 found on cancer cells, and then give them back to t…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for Hard-to-Treat ovarian cancer: experimental drug shows promise
Disease control Recruiting nowThis study tests a new drug called lorigerlimab in people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. About 60 participants will receive the drug by IV every 3 weeks. The goal is to see if the drug can shrink tumors and to c…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 22, 2026 13:54 UTC